植物多酚通过microRNA调控脂质代谢研究进展

microRNA（简称miRNA）是长度18~25个核苷酸的非编码RNA分子,具有调控mRNA的翻译和/或稳定性的功能,从而在转录后水平调节不同基因的表达。人体内约60%编码蛋白的基因的表达受到miRNA调节,其中包括脂质代谢调控相关基因。植物多酚具有良好的生物活性,可以通过调节脂质代谢相关miRNAs,如miR-122和miR-33的表达进而发挥降血脂等活性。该文综述了miRNA调控脂质代谢相关mRNA的作用机制以及植物多酚在这一过程中的可能作用。     

禽流感病毒核蛋白在噬菌体表面的展示

利用PCR技术,扩增禽流感病毒（AIV）核蛋白基因片段,将其克隆至pR质粒的T4噬菌体SOC基因C末端获得重组质粒pR—np,以此重组载体转化大肠杆菌Escherichia coli2（E2）,用溶菌酶缺陷噬菌体T4-zl感染重组E2菌,重组载体与缺陷噬菌体T4-zl基因发生同源重组,将np基因整合到噬菌体基因组中,用PCR方法筛选重组噬菌体并命名为T4-zl—np。经Western blot免疫电镜与ELISA检测证实,T4-zl-np表达的NP融合蛋白具有免疫学活性。结果表明,AIV核蛋白成功地在T4噬菌体表面展示,为禽流感防治奠定了基础。     

特异性分布于心脏的丝氨酸蛋白酶--Corin

蛋白酶参与心血管活性肽类的活化和降解 ,对其生物学效应具有重要的调节意义。丝氨酸蛋白酶是一类II型跨膜嵌合蛋白酶超家族 ,参与体内多种重要的生理过程。Corin是新发现的第一个特异性分布于心脏并参与心血管活性肽前体原转化的丝氨酸蛋白酶 ,可将心钠素原和脑钠素原转化为心钠素和脑钠素 ,并通过调控心钠素和脑钠素的生成而间接调节血压。本文简要介绍Corin的分子特征及生理和病理生理意义     

大分子量重组蛋白在丝状噬菌体表面的展示表达及其与小分子相互作用的初步研究

利用pHEN1KM13噬菌粒系统表达融合蛋白,进而确定大分子量重组蛋白在丝状噬菌体表达的部位及其表达后的生物活性。通过蛋白酶切处理前后噬菌体侵染细菌能力的变化快速地检测大分子蛋白质能否在噬菌体表面展示表达;比较了谷胱甘肽S转移酶及其与三个不同长度连接臂融合的外源蛋白在噬菌体表面的表达和组装,确定了不大于40kD的重组蛋白分子能展示表达在丝状噬菌体表面;并利用已知的小分子化合物与蛋白质的相互作用证明了组装在噬菌体表面的谷胱甘肽S转移酶重组蛋白仍保持其天然的结合活性,为利用噬菌体展示系统研究蛋白质与小分子化合物的相互作用建立了基础。     

神经元型一氧化氮合酶(nNOS)与疼痛

一氧化氮(NO)是神经元细胞内一种新型的神经递质,它由一氧化氮合酶(NOS)催化而成。在神经系统中神经元型一氧化氮合酶(nNOS)是NO合成的关键酶。大量研究表明,nNOS可调节多种生理和病理过程诸如炎性痛和神经病理性疼痛。该文通过介绍nNOS的结构、分布和影响nNOS活性的因素,阐述了nNOS在病理性疼痛中的重要作用,为此可通过调节nNOS表达来达到调节生理和病理过程。     

噬菌体抗体库技术

噬菌体抗体库技术是指从人外周血、脾或骨髓淋巴细胞提取总RNA,利用逆转录-多聚酶链反应（RT-PCR）方法扩增抗体的全套可变区基因,通过噬菌体表面展示技术,把抗体Fab段或单链抗体表达在噬菌体表面,构建人源抗体库.噬菌体抗体将基因型（genotype）和表型（phenotype）统一于一体,将选择能力和扩增能力偶联起来,具有强大的筛选能力,能够在体外模拟体内的抗体生成过程,使抗体工程技术进入了一个新的时代.     

蛋白激酶抑制剂噬菌体的构建和功能研究

人工合成编码ｃＡＭＰ信赖蛋白激酶（ｃＡＰＫ）的热稳定抑制剂第５－２４位氨基酸「ＰＫＩ（５－２４）」的ＤＮＡ片段,并将之克隆到ｐｈａｇｅ ｄｉｓｐｌａｙ载体ｆｄ－ｔｅｔ－ＤＯＧ１使中,使ＰＫＩ（５－２４）以融合于ｇ３ｐ蛋白的形式展示了噬菌体是到了ＰＫＩ噬菌体,蛋白激酶抑制活性测定表达ＰＫＩ噬菌体可有铲地抑制ＣＡＰＫ的活性。结合实验结果显示ＰＫＩ噬菌体能与固相化小鼠ＣＡＰＫ催化亚基α（Ｈｉｓ６－ｍＣα     

肾性高血压大鼠延髓尾端神经元型一氧化氮合酶表达的改变

实验采用免疫组织化学方法观察两肾一夹肾性高血压大鼠延髓尾端两个区域（延髓腹面降压区和尾端加压区）内神经元型一氧化氮合酶（neuronal oxide synthase,nNOS）表达的变化。肾性高血压大鼠延髓尾端这两个区域的nNOS的表达均增加,说明高血压对L-Arg-NO通路活性增强。NO的前体L-Arg能增强nNOS的表达,nNOS抑制剂L-NAME则降低nNOS的表达。以上两个区域nNOS表达变化的特点在肾性高血压4周和7周的动物相同,肾性高血压7周的nNOS表达和4周比较,未见明显差异。     

噬菌体表面表达抗汉坦病毒衣壳蛋白单链抗体的研究

噬菌体展示表达(Phage display expression)的主要特点是将特定分子的基因型和表型统一 在同一噬菌体颗粒内,其基因组中含有表达蛋白基因,在噬菌体表面进行特定的表达.该技 术为研制工程抗体提供一新的途径,在九十年代逐渐被人们认识并得到极其广泛的应用 [1,2].噬菌体表面表达技术适于表达Fv和Fab分子片段,当表达的抗体基因与噬菌 体外壳蛋白基因Ⅲ融合时,在噬菌体颗粒表面呈现单价表达,与噬菌体外壳蛋白基因Ⅷ融合时,呈现多价表达.     

神经病靶标酯酶调控结构域结合蛋白筛选及其在COS-7细胞中的表达

本研究采用酵母双杂交系统探寻与神经病靶标酯酶（NTE）调控结构域相互作用的蛋白因子,揭示与NTE信号转导相关的可能机制。通过构建含有NTE调控结构域的诱饵蛋白载体筛选胎脑文库,并将筛选得到的阳性克隆在酵母中进行了验证,随后在哺乳动物细胞中表达了该蛋白。生物信息学分析显示：该阳性克隆为前列腺素受体结合蛋白54（ARA54）,具有泛素连接酶活性,提示细胞可能存在依赖于细胞周期的NTE活性调节机制,为阐明NTE生理功能创造了条件[动物学报51（5）：840—844,2005]。     

脑型一氧化氮合成酶的钙调蛋白结合区的表达及活性鉴定

用PCR法克隆出nNOS的CaM结合区基因(nNOS 2455～2988bp),并在大肠杆菌中进行了高效表达。经金属离子螯合亲和层析得到纯度为90％以上的重组蛋白．分子量为22kDa,CaM Oveday assay证实该蛋白具有CaM的结合活性。由于所表达的重组蛋白既具有序列特异性又具有CaM的结合活性．因此。可将它作为筛选nNOS特异性抑制肽的靶蛋白,亦可用于特异性抗体的制备。     

Amphibian peptides that inhibit neuronal nitric oxide synthase. Isolation of lesuerin from the skin secretion of the Australian Stony Creek frog Litoria lesueuri.

Two neuropeptides have been isolated and identified from the secretions of the skin glands of the Stony Creek Frog Litoria lesueuri. The first of these, the known neuropeptide caerulein 1.1, is a common constituent of anuran skin secretions, and has the sequence pEQY(SO3)TGWMDF-NH2. This neuropeptide is smooth muscle active, an analgaesic more potent than morphine and is also thought to be a hormone. The second neuropeptide, a new peptide, has been named lesueurin and has the primary structure GLLDILKKVGKVA-NH2. Lesueurin shows no significant antibiotic or anticancer activity, but inhibits the formation of the ubiquitous chemical messenger nitric oxide from neuronal nitric oxide synthase (nNOS) at IC(50) (16.2 microm), and is the first amphibian peptide reported to show inhibition of nNOS. As a consequence of this activity, we have tested other peptides previously isolated from Australian amphibians for nNOS inhibition. There are three groups of peptides that inhibit nNOS (IC(50) at microm concentrations): these are (a) the citropin/aurein type peptides (of which lesueurin is a member), e.g. citropin 1.1 (GLFDVIKKVASVIGGL-NH(2)) (8.2 microm); (b) the frenatin type peptides, e.g. frenatin 3 (GLMSVLGHAVGNVLG GLFKPK-OH) (6.8 microm); and (c) the caerin 1 peptides, e.g. caerin 1.8 (GLFGVLGSIAKHLLPHVVPVIAEKL-NH(2)) (1.7 microm). From Lineweaver-Burk plots, the mechanism of inhibition is revealed as noncompetitive with respect to the nNOS substrate arginine. When the nNOS inhibition tests with the three peptides outlined above were carried out in the presence of increasing concentrations of Ca(2+) calmodulin, the inhibition dropped by approximately 50% in each case. In addition, these peptides also inhibit the activity of calcineurin, another enzyme that requires the presence of the regulatory protein Ca(2+) calmodulin. It is proposed that the amphibian peptides inhibit nNOS by interacting with Ca(2+)calmodulin, and as a consequence, blocks the attachment of this protein to the calmodulin domain of nNOS.     

Interaction of endothelial and neuronal nitric-oxide synthases with the bradykinin B2 receptor. Binding of an inhibitory peptide to the oxygenase domain blocks uncoupled NADPH oxidation

Endothelial nitric-oxide synthase (type III) (eNOS) was reported to form an inhibitory complex with the bradykinin receptor B2 (B2R) from which the enzyme is released in an active form upon receptor activation (Ju, H., Venema, V. J., Marrero, M. B., and Venema, R. C. (1998) J. Biol. Chem. 273, 24025-24029). Using a synthetic peptide derived from the known inhibitory sequence of the B2R (residues 310-329) we studied the interaction of the receptor with purified eNOS and neuronal nitric-oxide synthase (type I) (nNOS). The peptide inhibited formation of L-citrulline by eNOS and nNOS with IC(50) values of 10.6 +/- 0.4 microM and 7.1 +/- 0.6 microM, respectively. Inhibition was not due to an interference of the peptide with L-arginine or tetrahydrobiopterin binding. The NADPH oxidase activity of nNOS measured in the absence of L-arginine was inhibited by the peptide with an IC(50) of 3.7 +/- 0.6 microM, but the cytochrome c reductase activity of the enzyme was much less susceptible to inhibition (IC(50) >0.1 mM). Steady-state absorbance spectra of nNOS recorded during uncoupled NADPH oxidation showed that the heme remained oxidized in the presence of the synthetic peptide consisting of amino acids 310-329 of the B2R, whereas the reduced oxyferrous heme complex was accumulated in its absence. These data suggest that binding of the B2R 310-329 peptide blocks flavin to heme electron transfer. Co-immunoprecipitation of B2R and nNOS from human embryonic kidney cells stably transfected with human nNOS suggests that the B2R may functionally interact with nNOS in vivo. This interaction of nNOS with the B2R may recruit the enzyme to allow for the effective coupling of bradykinin signaling to the nitric oxide pathway.     

用随机6肽库筛选HGVE2抗原表位

利用抗 HGV E2区的 3株单克隆抗体 M6、M1 3、M30作为筛选配基 ,对随机 6肽库进行亲和筛选 . 3轮筛选的投入产出比逐轮升高至 3.5× 1 0 -3、假阳性率逐轮降低至 0 .4% ,提示具有良好的富集效果 .从第 3轮随机挑出 1 2个克隆进行功能鉴定 ,结果表明 8个克隆与 M6抗体有较强的特异性结合力并有较好的竞争抑制作用 ,测序发现它们的外源肽具有核心序列 :WA( W/Y) WXH,该序列与 HGV同源性低 ;用外源肽与核心序列相似的噬菌体克隆 P6GC9做竞争抑制试验 ,约 3×1 0 10个噬菌体即可较好地抑制 M6单抗与 HGV抗原结合 .该多肽可能是 HGV E2区识别 M6单抗并具有一定功能的模拟表位 .     

利用噬菌体随机肽库筛选可结合志贺毒素B亚单位的短肽序列

以制备的重组志贺毒素B亚单位(StxB)为靶标,利用噬菌体展示亲和淘选技术,经4轮筛选,从随机十二肽库中筛选到与StxB结合的一批噬菌体克隆,对特异结合活性较高的27个噬菌体克隆的表面展示肽进行序列测定,其中A6序列出现16次,A9和A3序列分别出现2次和3次。为评价筛选克隆中和毒素毒性的能力,将展示肽出现频率最高的A6噬菌体克隆,体外与志贺毒素孵育进行动物试验,动物存活率达33.3%,表明毒素的毒性得到部分抑制,A6短肽可能发展成为志贺毒素的拮抗剂。     

Amyloid-beta (25-35) increases activity of neuronal NO-synthase in rat brain

Nitric oxide (NO) is a free radical with multiple functions in the nervous system. NO plays an important role in the mechanisms of neurodegenerative diseases including Alzheimer's disease. The main source of NO in the brain is an enzymatic activity of nitric oxide synthase (NOS). The aim of the present study was to analyze the expression and activity of both neuronal (nNOS) and inducible (iNOS) isoenzymes in the cerebral cortex and hippocampus of rats after intracerebroventricular administration of amyloid-beta (A beta) peptide fragment A beta(25-35). NADPHd histochemistry as well as immunohistochemistry were also used to investigate nNOS and iNOS expression in rat brain. The data presented here show that A beta(25-35) did not influence levels of nNOS or iNOS mRNA or protein expression in both structures studied. A beta(25-35) activated nNOS in the cerebral cortex and hippocampus without effect on iNOS activity. A beta(25-35) decreased the number of NADPHd-expressing neurons in the neocortex, but it did not significantly influence the number NADPHd-positive cells in the hippocampus. The peptide had no effect on the number of nNOS containing cells. We hypothesize that increased synthesis of NO induced by A beta(25-35) is related to qualitative alterations of nNOS molecule, but not to changes in NOS protein expression.     

Binding of neuronal nitric-oxide synthase (nNOS) to carboxyl-terminal-binding protein (CtBP) changes the localization of CtBP from the nucleus to the cytosol: a novel function for targeting by the PDZ domain of nNOS

Recent work suggests a role for PDZ domains in the targeting of binding partners to specific sites in the cell. To identify whether the PDZ domain of neuronal nitric-oxide synthase (nNOS) can play such a role, we performed affinity chromatography of brain extract with the nNOS PDZ domain. We identified the carboxyl-terminal-binding protein (CtBP), a phosphoprotein first identified as a binding partner to adenovirus E1A, as a nNOS binding partner. CtBP interacts with the PDZ domain of nNOS, and this interaction can be competed with peptide that binds to the PDZ peptide-binding site. In addition, binding of CtBP to nNOS is dependent on its carboxyl-terminal sequence -DXL, residues conserved between species that fit the canonical sequence for nNOS PDZ binding. Immunoprecipitation studies show that CtBP and nNOS associate in the brain. When CtBP is expressed in Madin-Darby canine kidney cells, its distribution is primarily nuclear; however, when CtBP is co-expressed with nNOS, its localization becomes more cytosolic. This change in CtBP localization does not occur when its carboxyl-terminal nNOS PDZ binding motif is mutated or when CtBP is co-expressed with postsynaptic density 95, another PDZ domain-containing protein. Taken together, our data suggest a new function for nNOS as a regulator of CtBP nuclear localization.     

Control of electron transfer in nitric-oxide synthases. Swapping of autoinhibitory elements among nitric-oxide synthase isoforms

To clarify the role of the autoinhibitory insert in the endothelial (eNOS) and neuronal (nNOS) nitric-oxide synthases, the insert was excised from nNOS and chimeras with its reductase domain; the eNOS and nNOS inserts were swapped and put into the normally insertless inducible (iNOS) isoform and chimeras with the iNOS reductase domain; and an RRKRK sequence in the insert suggested by earlier peptide studies to be important (Salerno, J. C., Harris, D. E., Irizarry, K., Patel, B., Morales, A. J., Smith, S. M., Martasek, P., Roman, L. J., Masters, B. S., Jones, C. L., Weissman, B. A., Lane, P., Liu, Q., and Gross, S. S. (1997) J. Biol. Chem. 272, 29769-29777) was mutated. Insertless nNOS required calmodulin (CaM) for normal NOS activity, but the Ca(2+) requirement for this activity was relaxed. Furthermore, insert deletion enhanced CaM-free electron transfer within nNOS and chimeras with the nNOS reductase, emphasizing the involvement of the insert in modulating electron transfer. Swapping the nNOS and eNOS inserts gave proteins with normal NOS activities, and the nNOS insert acted normally in raising the Ca(2+) dependence when placed in eNOS. Insertion of the eNOS insert into iNOS and chimeras with the iNOS reductase domain significantly lowered NOS activity, consistent with inhibition of electron transfer by the insert. Mutation of the eNOS RRKRK to an AAAAA sequence did not alter the eNOS Ca(2+) dependence but marginally inhibited electron transfer. The salt dependence suggests that the insert modulates electron transfer within the reductase domain prior to the heme/reductase interface. The results clarify the role of the reductase insert in modulating the Ca(2+) requirement, electron transfer rate, and overall activity of nNOS and eNOS.     

Identification of caveolin-1-interacting sites in neuronal nitric-oxide synthase. Molecular mechanism for inhibition of NO formation

Caveolin is known to down-regulate both neuronal (nNOS) and endothelial nitric-oxide synthase (eNOS). In the present study, direct interactions of recombinant caveolin-1 with both the oxygenase and reductase domains of nNOS were demonstrated using in vitro binding assays. To elucidate the mechanism of nNOS regulation by caveolin, we examined the effects of a caveolin-1 scaffolding domain peptide (CaV1p1; residues (82-101)) on the catalytic activities of wild-type and mutant nNOSs. CaV1p1 inhibited NO formation activity and NADPH oxidation of wild-type nNOS in a dose-dependent manner with an IC(50) value of 1.8 microM. Mutations of Phe(584) and Trp(587) within a caveolin binding consensus motif of the oxygenase domain did not result in the loss of CaV1p1 inhibition, indicating that an alternate region of nNOS mediates inhibition by caveolin. The addition of CaV1p1 also inhibited more than 90% of the cytochrome c reductase activity in the isolated reductase domain with or without the calmodulin (CaM) binding site, whereas CaV1p1 inhibited ferricyanide reductase activity by only 50%. These results suggest that there are significant differences in the mechanism of inhibition by caveolin for nNOS as compared with those previously reported for eNOS. Further analysis of the interaction through the use of several reductase domain deletion mutants revealed that the FMN domain was essential for successful interaction between caveolin-1 and nNOS reductase. We also examined the effects of CaV1p1 on an autoinhibitory domain deletion mutant (Delta40) and a C-terminal truncation mutant (DeltaC33), both of which are able to form NO in the absence of CaM, unlike the wild-type enzyme. Interestingly, CaV1p1 inhibited CaM-dependent, but not CaM-independent, NO formation activities of both Delta40 and DeltaC33, suggesting that CaV1p1 inhibits interdomain electron transfer induced by CaM from the reductase domain to the oxygenase domain.